• Publications
  • Influence
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
PURPOSE Febrile neutropenia remains a potentially life-threatening complication of anticancer chemotherapy, but some patients are at low risk for serious medical complications. The purpose of thisExpand
  • 909
  • 60
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
Despite the relevant progress achieved in the last 20 years,vomiting and, especially, nausea, continue to be two of themost distressing side-effects of cancer chemotherapy. In the late1990s severalExpand
  • 612
  • 55
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
PURPOSE This randomized, double-blind, placebo-controlled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic parameters, quality of life (QOL), and safetyExpand
  • 979
  • 23
Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy
PURPOSE: This phase III study compared docetaxel with mitomycin plus vinblastine (MV) in patients with metastatic breast cancer (MBC) progressing despite previous anthracycline-containingExpand
  • 517
  • 20
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.
Management of febrile neutropenia: ESMO Clinical Practice Guidelines J. de Naurois, I. Novitzky-Basso, M. J. Gill, F. Marti Marti, M. H. Cullen & F. Roila On behalf of the ESMO Guidelines WorkingExpand
  • 283
  • 17
Bacteraemia in febrile neutropenic cancer patients.
A total of 2142 patients with febrile neutropenia resulting from cancer chemotherapy were registered in two observational studies and followed prospectively in different institutions. There were 499Expand
  • 247
  • 12
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
F. Roila1, A. Molassiotis2, J. Herrstedt3, M. Aapro4, R. J. Gralla5, E. Bruera6, R. A. Clark-Snow7, L. L. Dupuis8, L. H. Einhorn9, P. Feyer10, P. J. Hesketh11, K. Jordan12, I. Olver13, B. L.Expand
  • 207
  • 10
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
PurposeAprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in breast cancer patientsExpand
  • 138
  • 7
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a significant adverse impact on patient health-related quality of life andExpand
  • 65
  • 6
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
Development of effective antiemetic therapy depends upon an understanding of both the antiemetic agents and the emetogenic challenges these agents are designed to address. New potential antiemeticExpand
  • 166
  • 5
  • PDF